Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Tumor Lysis Syndrome 3Recurrence 1Neoplasms 1Lymphoma 1Leukemia 1Hyperuricemia 1Hematologic Neoplasms 1

Interventions

nilotinib 4Cytarabine 3Filgrastim 2Cyclophosphamide 2Aprepitant 2Antilymphocyte Serum 2rasburicase 1liposomal amphotericin B 1fludarabine phosphate 1fludarabine 1bosutinib 1blinatumomab 1aldesleukin 1Water 1Voriconazole 1Urate Oxidase 1Tobacco Use Cessation Devices 1Thiotepa 1Rituximab 1Radiotherapy 1Psychiatric Rehabilitation 1Prilocaine 1Polymerase Chain Reaction 1Pharmacogenomic Testing 1Pentostatin 1Palonosetron 1Oxygen 1Interleukin-2 1Inotuzumab Ozogamicin 1Histamine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Leukemia × Urate Oxidase × Clear all
NCT00230217 2009-03-30

Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy

Sanofi

Phase 4 Completed
94 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Neoplasms, Recurrence, Tumor Lysis Syndrome, Hyperuricemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡